CAS 923590-37-8

Vaniprevir

Description:

Vaniprevir is an antiviral compound primarily developed for the treatment of hepatitis C virus (HCV) infections. It belongs to the class of direct-acting antiviral agents known as NS3/4A protease inhibitors, which function by inhibiting the viral protease enzyme essential for the replication of the virus. The molecular structure of vaniprevir includes a complex arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, contributing to its pharmacological properties. It exhibits a moderate to high lipophilicity, which influences its absorption and distribution in the body. Vaniprevir has shown efficacy in clinical trials, often used in combination with other antiviral agents to enhance therapeutic outcomes. Its mechanism of action involves binding to the active site of the NS3 protease, thereby preventing the cleavage of viral polyproteins and subsequent viral replication. As with many antiviral medications, potential side effects may include gastrointestinal disturbances and effects on liver function, necessitating careful monitoring during treatment. Overall, vaniprevir represents a significant advancement in the pharmacotherapy of hepatitis C.

Formula: C₃₈H₅₅N₅O₉S

InChI: InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1

InChI key: InChIKey=KUQWGLQLLVFLSM-ONAXAZCASA-N

SMILES: N(C(=O)[C@H]1N2C[C@@](C1)(OC(=O)N3CC=4C(C3)=CC=CC4CCCCC(C)(C)COC(=O)N[C@@H]([C@](C)(C)C)C2=O)[H])[C@@]5(C(NS(=O)(=O)C6CC6)=O)[C@H](CC)C5

Synonyms:

• (1R,2R)-N-[[[6-(2-Carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethylcyclopropanecarboxamide (1-2)-lactone
• Cyclopropanecarboxamide, N-[[[6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl]oxy]carbonyl]-3-methyl-<span class="text-smallcaps">L</smallcap>-valyl-(4R)-4-hydroxy-<smallcap>L</span>-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1→2)-lactone, (1R,2R)-
• Mk 7009
• Vanihep
• Cyclopropanecarboxamide, N-[[[6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1→2)-lactone, (1R,2R)-
• Vaniprevir
• Vaniprevir(MK-7009)
• MK 7009/Vaniprevir
• MK-7009;MK7009;MK 7009

Vaniprevir

CAS: 923590-37-8

Formula: C₃₈H₅₅N₅O₉S

Molecular weight: 757.9364

Ref: IN-DA00GU79

Vaniprevir

CAS: 923590-37-8

Vaniprevir

Purity: ≥95%

Molecular weight: 757.94g/mol

Ref: 54-BUP20022

Vaniprevir

CAS: 923590-37-8

Vaniprevir is a potent inhibitor of the NS3/4A protease, a viral enzyme that is essential for hepatitis C virus replication. It has been shown to be an effective treatment for hepatitis C in patients with high levels of resistance. Vaniprevir inhibits viral life cycle by binding to the active site of the NS3/4A protease and preventing cleavage of the polyprotein into functional proteins. Vaniprevir also prevents replication of HIV-1 by inhibiting the NS3/4A protease.

Formula: C₃₈H₅₅N₅O₉S

Purity: Min. 95%

Molecular weight: 757.94 g/mol

Ref: 3D-FV159262

Vaniprevir

CAS: 923590-37-8

Vaniprevir is a competitive HCV NS3/4A protease inhibitor, an antiviral(hepatitis C virus) drug that acts directly and blocks the viral replication process.

Formula: C₃₈H₅₅N₅O₉S

Purity: 97.41%

Color and Shape: Solid

Molecular weight: 757.94

Ref: TM-T8675